Chimeric Therapeutics (ASX:CHM) Inventories, Finished Goods: A$0.00 Mil (As of Dec. 2025)


What is Chimeric Therapeutics Inventories, Finished Goods?

Chimeric Therapeutics ASX:CHM Inventories, Finished Goods is A$0.00 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

Chimeric Therapeutics Inventories, Finished Goods Historical Data

* Premium members only.

The historical data trend for Chimeric Therapeutics's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chimeric Therapeutics Inventories, Finished Goods Chart

Chimeric Therapeutics Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Inventories, Finished Goods
0.00 0.00 0.00 0.00 0.00

Chimeric Therapeutics Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Chimeric Therapeutics Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

What does a Inventories, Finished Goods of A$0.00 Mil mean?
Chimeric Therapeutics (ASX:CHM) has a Inventories, Finished Goods of A$0.00 Mil as of Dec. 2025. Finished goods are inventory items that are complete and ready to be sold. View historical data on Chimeric Therapeutics and its competitors.
Is Chimeric Therapeutics' Inventories, Finished Goods too high?
Chimeric Therapeutics' current Inventories, Finished Goods is A$0.00 Mil.
How does Chimeric Therapeutics' Inventories, Finished Goods compare to VRTX and REGN?
Chimeric Therapeutics' Inventories, Finished Goods of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Finished Goods for a Biotechnology company?
A good Inventories, Finished Goods depends on the Biotechnology industry context. However, Inventories, Finished Goods should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Finished Goods mean?
A high Inventories, Finished Goods can signal that a stock is expensive relative to its fundamentals. Finished goods are inventory items that are complete and ready to be sold. View historical data on Chimeric Therapeutics and its competitors. Chimeric Therapeutics's current Inventories, Finished Goods is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chimeric Therapeutics stock overvalued right now?
Chimeric Therapeutics (ASX:CHM) has a current Inventories, Finished Goods of A$0.00 Mil. The current Inventories, Finished Goods is A$0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Finished Goods calculated?
Inventories, Finished Goods is calculated from a company's financial statements. For Chimeric Therapeutics (ASX:CHM), the current Inventories, Finished Goods is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Chimeric Therapeutics Business Description

Address 62 Lygon Street, Level 3, Carlton, Melbourne, VIC, AUS, 3053
Chimeric Therapeutics Ltd is an Australian clinical-stage cell therapy company focused on developing and commercialising a range of cell therapies in oncology. The group's products under development include T Cell Derived Autologous Therapies and Natural Killer (NK) Cell Derived Allogenic Therapies. T Cell Derived Autologous therapy works by engineering the T cells with the exact coordinates to attack and kill cancer. NK Cell Derived Allogenic Therapies from healthy donors can be manufactured on a large scale and, once administered, kill cancer. Its pipeline products include CDH17, CLTX, and CORE NK. The group has one reportable segment, being the research, development, and commercialisation of health technologies.